| Patent application number | Description | Published |
|---|
| 20100249531 | MEDICAL HEALTH INFORMATION SYSTEM - A system and method determine and report a potential for development by a patient of disease and adverse health conditions. The method includes receiving patient phenotype data. The phenotype data can include, but is not limited to, biometric data specific to the patient, medical claims data specific to the patient, and organizational data specific to an organization to which the patient belongs. One or more predictive models are generated using one or more algorithms executing on at least one processor of a computing apparatus. The one or more predictive models determine and indicate the potential for development by the patient of disease and adverse health conditions, and output the potential to a user. | 09-30-2010 |
| 20120072233 | MEDICAL HEALTH INFORMATION SYSTEM FOR HEALTH ASSESSMENT, WEIGHT MANAGEMENT AND MEAL PLANNING - A system and method provide nutrition assessments and tools for enabling users to achieve health-related goals based on specific health needs. The tools can include a nutrition assessment tool, a weight solution tool, a meal planning tool, and a meal tracking tool. The method includes receiving patient phenotype data. The phenotype data can include, but is not limited to, biometric data specific to the patient, medical claims data specific to the patient, organizational data specific to an organization to which the patient belongs, and behavioral data including dietary habits and nutritional history. One or more algorithms are executed on at least one processor of a computing apparatus to provide analyses of patient data in order. The results are output to a user in various web pages customized to provide features to the user. | 03-22-2012 |
| 20120290327 | MEDICAL HEALTH INFORMATION SYSTEM FOR HEALTH ASSESSMENT, WEIGHT MANAGEMENT AND MEAL PLANNING - A system and method provide nutrition assessments and tools for enabling users to achieve health-related goals based on specific health needs. The tools can include a nutrition assessment tool, a weight solution tool, a meal planning tool, and a meal tracking tool. The method includes receiving patient phenotype data. The phenotype data can include, but is not limited to, biometric data specific to the patient, medical claims data specific to the patient, organizational data specific to an organization to which the patient belongs, and behavioral data including dietary habits and nutritional history. One or more algorithms are executed on at least one processor of a computing apparatus to provide analyses of patient data in order. The results are output to a user in various web pages customized to provide features to the user. | 11-15-2012 |
| 20130244965 | ASSAYS AND METHODS FOR DETERMINING RISK OF A MACROPHAGE-MEDIATED DISEASE DEVELOPMENT IN A SUBJECT INFECTED WITH HIV - The invention is generally related to assays and methods for determining the risk of an HIV+ individual for developing a macrophage-mediated disease using measurement of soluble CD163 levels in a biological sample. The invention also provides assays and methods for monitoring efficacy of a treatment or a drug for a macrophage-mediated disease, and assays and methods for screening for agents to treat a macrophage-mediated disease in an HIV+ individual by monitoring soluble CD163 levels. | 09-19-2013 |
| Patent application number | Description | Published |
|---|
| 20110053850 | DOC1 COMPOSITIONS AND METHODS FOR TREATING CANCER - A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth. | 03-03-2011 |
| 20110177971 | METHOD FOR DIAGNOSING THE STAGE OF A THYROID TUMOR - The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer. | 07-21-2011 |
| 20110319289 | MOLECULAR-BASED METHOD OF CANCER DIAGNOSIS AND PROGNOSIS - A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes. Thus, provided herein is a method of determining the prognosis of a subject with a tumor by detecting expression of five of more cancer survival factor-associated genes in a tumor sample and comparing expression of the five or more cancer survival factor-associated genes in the tumor sample to a control. In some examples, an increase in expression of ABCF1, CORO1C, DPP3, PREB, UBE3A, and PTDSS1 in a tumor sample compared to a control sample indicates poor prognosis. Also provided is a method of treating a patient diagnosed with cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed cancer survival factor-associated genes. Further provided are arrays including probes or antibodies specific for a plurality of cancer survival factor-associated genes or proteins. | 12-29-2011 |
| 20140039041 | FILIP1L COMPOSITIONS AND METHODS FOR TREATING CANCER - A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth. | 02-06-2014 |
| Patent application number | Description | Published |
|---|
| 20080251485 | Container Crane - A container crane includes a container including first and second side walls spaced apart and generally parallel, a bridge adapted to travel in a substantially longitudinal direction along the first and second side walls, a trolley adapted to travel in a substantially longitudinal direction along the bridge, a jib coupled to a bottom surface of the trolley, and a hoist mounted to the jib. | 10-16-2008 |
| 20090123255 | CANISTER TRANSFER SYSTEM WITH INDEPENDENT TRAVELING SHIELDED BELL - A transfer system for spent fuel canisters includes a carrier, a shielded bell trolley movable along the carrier and carrying a shielded bell, and a canister trolley movable along the carrier and carrying a lifting mechanism for raising and lowering the spent fuel canister into and out of the shielded bell. The canister trolley can move along the carrier independent of the shielded bell trolley and the shielded bell trolley can move along the carrier independent of the canister trolley. The shielded bell trolley and the canister trolley can be selectively interlocked for selected transfer operations. | 05-14-2009 |
| 20090159548 | OVERHEAD CRANE - An overhead crane adapted to be supported by at least one main support beam includes a bridge adapted to travel in a substantially horizontal direction along the at least one main support beam, a trolley adapted to travel in a substantially horizontal direction along the bridge, a jib rotatably coupled to a bottom surface of the trolley, and a hoist adapted to travel in a substantially horizontal direction along the jib. | 06-25-2009 |
| 20090232634 | METHOD AND A DEVICE FOR LIFTING AND ROTATING A MASSIVE CONTAINER - A device and method for lifting and rotating a massive container comprising a base frame assembly, a cradle pivotally connected to the base frame assembly and adapted to hold the container, a mechanism for moving the container vertically relative to at least part of the base frame assembly, and a hydraulic cylinder connected between the base frame assembly and the cradle for rotating in a vertical plane the cradle relative to the base frame assembly. | 09-17-2009 |
| 20090250423 | PIN CHANGING DEVICE AND METHOD - A pin removal assembly for use with an upper block of a crane includes a sheave support and a pin support. The upper block includes a frame, a plurality of sheaves, and a removable sheave pin that defines and axis of rotation for the sheaves and supports the sheaves within the frame. The pin removal assembly includes a sheave support mountable to the frame of the upper block and a pin support mountable to the frame of the upper block. The pin support is configured to support the sheave pin when the sheave pin is removed from the upper block. | 10-08-2009 |
| 20100018938 | UPPER BLOCK - A crane having an upper block, a lower block, a drum, and two ropes. The upper block includes an equalizer having a yoke to which the ropes are connected. The connections between the ropes and the yoke include load cells that measure the forces carried by each of the ropes. The upper block includes a fail-safe system that prevents failure of the upper block in overload conditions. | 01-28-2010 |
| 20100272224 | FUEL TRANSFER SYSTEM - A fuel transfer system is used for transporting spent fuel from a first room to a second room. The system includes a carriage configured for travel between the first room and the second room, and a boom assembly that extends and retracts between the first room and the second room, wherein the boom assembly facilitates travel of the carriage. The system also includes a hoist system positioned in the first room. The hoist system includes at least one boom cable interconnected with the boom assembly to extend and retract the boom assembly. The hoist system also includes at least one carriage cable interconnected with the carriage to move the carriage. | 10-28-2010 |
| 20120192405 | PIN CHANGING DEVICE AND METHOD - A pin removal assembly for use with an upper block of a crane includes a sheave support and a pin support. The upper block includes a frame, a plurality of sheaves, and a removable sheave pin that defines and axis of rotation for the sheaves and supports the sheaves within the frame. The pin removal assembly includes a sheave support mountable to the frame of the upper block and a pin support mountable to the frame of the upper block. The pin support is configured to support the sheave pin when the sheave pin is removed from the upper block. | 08-02-2012 |
| 20130045070 | CASK HANDLING SYSTEM AND METHOD - A system and method for removing spent fuel assemblies from a fuel building and transporting them to on-site facilities. A cask transporter is moved into the fuel building with an empty spent fuel storage cask, spent fuel assemblies are loaded into spent fuel storage cask, the cask is sealed, and the cask transporter moves the loaded spent fuel storage cask to a handling area for final disposal. Components of the system include a penetration cover, a lifting mechanism, a control system, a valve system, and the cask transporter. | 02-21-2013 |
| 20130117999 | WORK PLATFORM FOR AN OVERHEAD CRANE - A work platform for use in performing maintenance while supported on an overhead crane. The work platform is particularly useful for performing maintenance on an overhead cranes located in areas where normal lifting equipment and/or scaffolding cannot easily access the overhead crane. However, the work platform is also useful for performing maintenance on equipment and/or structures in the vicinity of overhead cranes, and on overhead cranes located in areas without accessibility problems. The work platform is hoisted for placement on the support structure of the overhead crane by hoist apparatus of the overhead crane. When positioned, the work platform may be fully supported on the support structure of the overhead crane. | 05-16-2013 |
| Patent application number | Description | Published |
|---|
| 20090258850 | STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS - The invention relates to pharmaceutically acceptable formulations comprising an active pharmaceutical ingredient such as androst-5-ene-3β,17β-diol, androst-5-ene-3β,7β,17β-triol or derivatives of either of these compounds and an air oxidizable excipient that have been stabilized with respect to efficacy. Use of the efficacy-stabilized formulations to treat a number of conditions or symptoms thereof, such as a symptom associated with exposure to radiation is described. | 10-15-2009 |
| 20090291932 | PHARMACEUTICAL SOLID STATE FORMS - The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions. | 11-26-2009 |
| 20090291933 | SOLID STATE FORMS OF A PHARMACEUTICAL - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 11-26-2009 |
| 20090326251 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS - The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S, 10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors. | 12-31-2009 |
| 20120214987 | METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS - The invention relates to processes for preparing 3α-O-linked steroids including 3α-O-linked-androst-5-ene steroids and 3α-O-linked-5a-androstane steroids. In one process a 3α,4α-epoxy androst-5-en-17-one is predominately reduced at the epoxy moiety wherein reduction of the 3α,4α epoxy functional group occurs preferentially at position C4 with retention of configuration at position C3 to provide a 3α-O-linked-androst-5-ene steroid. In another process, conditions are provided for inversion of configuration of a 3β-hydroxy-androst-5-ene steroid by the Mitsunobu reaction to provide a 3α-O-linked-androst-5-ene steroid with reduced amounts of 3α,5α-cycloandrostane side-product impurities. | 08-23-2012 |
| 20120220560 | STEROID TETROL SOLID STATE FORMS - The invention relates to solid state forms of androst-5-ene-3β,7β,16α,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes. | 08-30-2012 |
| 20120252774 | STEROID TETROL SOLID STATE FORMS - 2 - The invention relates to solid state forms of androst-5-ene-3α,7β,16β,17β-tetrol, formulations containing or prepared from such solid state forms and use of these materials for modulating unwanted inflammation including acute and chronic non-productive inflammation. The formulations can be used to prevent, treat or slow the progression of conditions related to autoimmunity and metabolic disorders such as arthritis, multiple sclerosis, ulcerative colitis, Type 1 diabetes and Type 2 diabetes. | 10-04-2012 |
| 20120296105 | CRYSTALLINE ANHYDRATE FORMS OF A PHARMACEUTICAL - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 11-22-2012 |
| 20120302537 | TREATMENT METHODS USING PHARMACEUTICAL SOLID STATE FORMS - The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions. | 11-29-2012 |
| 20130066087 | METHODS FOR PREPARING 17-ALKYNYL-7-HYDROXY STEROIDS AND RELATED COMPOUNDS-2 - The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors. | 03-14-2013 |
| 20130338125 | TREATMENT METHODS USING PHARMACEUTICAL SOLID STATE FORMS - The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions. | 12-19-2013 |
| 20130345184 | PHARMACEUTICAL SOLID STATE FORMS-2 - The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions. | 12-26-2013 |
| 20130345455 | METHODS OF PREPARING PHARMACEUTICAL SOLID STATE FORMS - The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions. | 12-26-2013 |
